DEINOVE SA, a biotech company, discovers, develops, and produces compounds originating from microbials for the health, nutrition, and cosmetics industries worldwide. The company's antibiotic candidates include DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers PHYT-N-Resist, an anti-aging active ingredient for cosmetics; Luminity, a carotenoid-based ingredient to absorb blue light and exceptional antioxidant properties; HEBELYS, a natural active ingredient produced by fermentation of Sphingomonas; and BIOME Oléoactif, which acts as a post-biotic extract with a prebiotic effect to balance the skin microbiota. In addition, the company develops a process for producing natural ingredients for animal feed. DEINOVE SA has partnership agreements primarily with bioMérieux, Naicons, Medpace, Institut Pasteur, Hallstar Group, Sharon Laboratories, Oléos-Hallstar, Greentech, and Avril. The company was founded in 2006 and is headquartered in Grabels, France.

ALDE

EURONEXT:ALDEI

Deinove SA

Last Close

0.03

10/01 16:35

Market Cap

1.13M

Beta: 0.79

Volume Today

13.01M

Avg: 5.99M

PE Ratio

−0.11

PFCF: −0.18

locale

market

industry

website

ipo date

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics